An advisory panel to the U.S. Food and Drug Administration is expected to meet later Tuesday to review the vaccine developed by Novavax Inc. NVAX, with a vote expected to influence the agency's decision on whether the risks outweigh the benefits. The FDA said last week that the company's experimental two-dose vaccine could have a higher risk for myocarditis than what was reported for the mRNA vaccines since they were authorized. The company countered by saying there was insufficient evidence to establish a causal relationship between its COVID 19 vaccine candidate and instances of myocarditis and pericarditis. It has a 90% efficacy rate against mild to severe symptomatic COVID - 19. The New York Times said that the U.S. cases are averaging 98,867 cases a day, down 8% from two weeks ago. The country is averaging 29,299 hospitalizations a day, up 15% from two weeks ago. The death toll has fallen to 266 on average, down 15% from two weeks ago. Total cases are now over 532.4 million on a global basis. The U.S. still leads the way with 84.9 million cases and 1,008, 857 deaths, according to data collected by Johns Hopkins University.